Immunocore Limited

116 articles about Immunocore Limited

• Immunocore to present at upcoming April 2024 investor conferences

  4/4/2024

  Immunocore Holdings plc, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, announced that management will participate in the following investor conferences in April.

• Immunocore presented two posters at CROI 2024

  3/5/2024

  Immunocore Holdings plc presented two posters at the 2024 Conference on Retroviruses and Opportunistic Infections.

• Immunocore to present at upcoming March 2024 investor conferences

  3/1/2024

  Immunocore Holdings plc, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, announced that management will participate in the following investor conferences in March.

• Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

  2/28/2024

  Immunocore Holdings plc today announced its financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.

• Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

  2/22/2024

  Immunocore Holdings plc announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to investigate Immunocore’s ImmTAC bispecific TCR candidate targeting PRAME HLA-A02, IMC-F106C, in combination with Bristol Myers Squibb’s nivolumab, in first-line advanced cutaneous melanoma.

• Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

  2/21/2024

  Immunocore Holdings plc today announced that it will report full year 2023 results, before the US markets open on Wednesday, February 28, 2024.

• Immunocore Prices Upsized Convertible Senior Notes Offering

  1/31/2024

  Immunocore Holdings plc announced the pricing of $350.0 million aggregate principal amount of 2.50% convertible senior notes due 2030 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

• Immunocore Announces Proposed Convertible Senior Notes Offering - Jan 29, 2024

  1/29/2024

  Immunocore Holdings plc, announced its intention to offer, subject to market and other conditions, $300.0 million aggregate principal amount of convertible senior notes due 2030 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

• Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference

  1/3/2024

  Immunocore Holdings plc announced that management will participate in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

• Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update

  11/7/2023

  Immunocore Holdings plc announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

• Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023

  11/1/2023

  Immunocore Holdings plc will present data for KIMMTRAK in metastatic uveal melanoma and cutaneous melanoma at the Society for Immunotherapy of Cancer's Annual Meeting and the Society for Melanoma Research Congress.

• Immunocore to present at upcoming November 2023 investor conferences

  10/30/2023

  Immunocore Holdings Plc announced that management will present at the following investor conferences in November:

• Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial

  10/21/2023

  Immunocore Holdings plc announces that the three-year overall survival data from the KIMMTRAK Phase 3 trial in previously untreated HLA-A*02:01 positive patients with metastatic uveal melanoma has been published in The New England Journal of Medicine, and presented as a late breaking abstract in a mini oral session at the European Society for Medical Oncology Congress 2023.

• Immunocore to present at upcoming investor conferences - September 11, 2023

  9/11/2023

  Immunocore Holdings Plc announced that management will present at the following investor conferences in September:

• Immunocore to present at upcoming September 2023 investor conferences

  9/1/2023

  Immunocore Holdings Plc announced that management will present at the following investor conferences in September.

• Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update

  8/10/2023

  Immunocore Holdings plc announced its financial results for the second quarter ended June 30, 2023, and provided a business update.

• Immunocore to report second quarter 2023 financial results and host call on August 10, 2023

  8/3/2023

  Immunocore Holdings Plc announced that it will report second quarter financial results, before the US markets open on Thursday, August 10, 2023.

• Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO

  6/3/2023

  Immunocore Holdings plc is presenting two posters at the 2023 American Society for Clinical Oncology meeting.

• Immunocore to present at upcoming June 2023 investor conferences

  6/1/2023

  Immunocore Holdings Plc, a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, announced that management will present at the following investor conferences in June:

• Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival

  4/18/2023

  Immunocore Holdings plc has presented four posters with KIMMTRAK data in HLA-A*02:01 patients with metastatic uveal melanoma, at the 2023 American Association for Cancer Research Annual Meeting 2023.